Education
About Us
Working with TipRanks
Follow Us
AngioDynamics (ANGO)
NASDAQ:ANGO
Top Page
AngioDynamics
(NASDAQ:ANGO)
50Neutral
Positive Factors
Financial Performance
AngioDynamics reported a top and bottom-line beat in fiscal 3Q25, with FY2025 guidance increased.
Market Expansion
ANGO's stock is undervalued for the access to multiple high-growth markets it already has, along with the potential further upside from its ability to enter both DVT and coronary markets in the future.
Product Innovation
The company's AlphaVac is differentiated from its competition in a variety of ways, including saving procedure time and having features like a funnel shaped tip which can remove more clot burden.
Regulatory Approval
FDA approves NanoKnife System for prostate tissue ablation.
Negative Factors
Market Competition
There is strategic interest in ANGO, especially following high EV/Sales multiples paid by other companies for similar businesses.
Market Maturity
ANGO should see continued growth in Auryon, but likely more moderated comparatively over the long term given atherectomy is a mature market.
AngioDynamics (ANGO) vs. S&P 500 (SPY)
Market Cap
$350.44M
Dividend YieldN/A
Average Volume (3M)525.60K
Price to Earnings (P/E)―
Beta (1Y)0.22
Revenue Growth-12.56%
EPS Growth78.70%
CountryUS
Employees748
SectorHealthcare
Sector Strength53
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)-0.08
Shares Outstanding40,606,987
10 Day Avg. Volume265,265
30 Day Avg. Volume525,603
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit2.19
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$15.50Price Target Upside76.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
AngioDynamics Business Overview & Revenue Model
Company DescriptionAngioDynamics, Inc. is a leading provider of innovative medical, surgical, and diagnostic devices used by professional healthcare providers for the minimally invasive treatment of cancer and peripheral vascular disease. The company operates in the healthcare sector, focusing on the development and commercialization of products that improve patient outcomes and reduce healthcare costs. AngioDynamics markets a wide range of devices, including radiofrequency ablation systems, vascular access products, and thrombolytic products, serving hospital, outpatient center, and physician office markets globally.
How the Company Makes MoneyAngioDynamics generates revenue primarily through the sale of its medical devices and products to healthcare providers. The company's key revenue streams include direct sales to hospitals and healthcare facilities, as well as distribution agreements with third-party distributors. AngioDynamics leverages its extensive sales network and strategic partnerships to expand its market reach and enhance its product offerings. Revenue is also driven by the company's focus on research and development, resulting in innovative products that address unmet clinical needs. Additionally, AngioDynamics may earn revenue through licensing agreements and collaborations with other medical technology companies, contributing to its overall earnings.
AngioDynamics Financial Statement Overview
Summary
AngioDynamics is facing financial headwinds characterized by declining revenues, negative profitability margins, and cash flow challenges. While the balance sheet reflects a strong equity position and no current debt, the company's ability to generate cash and profit remains weak. Strategic improvements in operational efficiency and revenue growth are necessary for financial health enhancement.Income Statement
AngioDynamics has experienced a decline in revenue, with a negative revenue growth rate over the past year from $338.75M to $286.50M TTM. Gross profit margin is around 50.66% TTM, indicating efficiency in managing production costs. However, the company is facing significant challenges with negative EBIT and net income margins, reflecting ongoing profitability issues.45
Neutral
Balance Sheet
The company maintains a strong equity position with an equity ratio of approximately 64.05% TTM, indicating a solid capital structure. Absence of debt in the latest period reduces financial risk. However, the negative return on equity suggests that the company is not generating sufficient returns for shareholders.55
Neutral
Cash Flow
AngioDynamics is struggling with negative operating and free cash flows, which impacts its ability to reinvest or reduce liabilities. The free cash flow growth rate is negative, highlighting cash flow management issues. The operating cash flow to net income ratio is concerning, signaling poor conversion of income to cash.40
Negative
| Breakdown | ||||
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 303.91M | 338.75M | 316.22M | 291.01M | 264.16M | Gross Profit |
| 154.70M | 174.25M | 165.73M | 156.79M | 150.27M | EBIT |
| -192.44M | -19.23M | -19.01M | -14.87M | -14.17M | EBITDA |
| -14.29M | 12.19M | 11.13M | -8.90M | -143.74M | Net Income Common Stockholders |
| -184.35M | -52.44M | -26.55M | -31.55M | -165.79M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 76.06M | 44.62M | 28.82M | 48.16M | 54.44M | Total Assets |
| 317.67M | 532.64M | 552.75M | 561.44M | 595.51M | Total Debt |
| 5.91M | 49.82M | 33.78M | 20.00M | 40.84M | Net Debt |
| -71.33M | 5.20M | 4.96M | -28.16M | -13.60M | Total Liabilities |
| 112.08M | 154.34M | 128.26M | 121.98M | 139.64M | Stockholders Equity |
| 205.59M | 378.30M | 424.49M | 439.46M | 455.87M |
| Cash Flow | Free Cash Flow | |||
| -33.93M | -4.27M | -11.49M | 10.38M | -22.14M | Operating Cash Flow |
| -28.16M | 78.00K | -7.19M | 24.09M | -14.55M | Investing Cash Flow |
| 123.72M | -9.75M | -19.31M | -13.71M | -63.34M | Financing Cash Flow |
| -64.25M | 25.42M | 7.68M | -16.99M | -95.24M |
AngioDynamics Technical Analysis
Negative
8.77
Price Trends
9.43
Negative
10.01
Negative
8.61
Positive
Market Momentum
-0.18
Positive
40.03
Neutral
9.40
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANGO, the sentiment is Negative. The current price of 8.77 is below the 20-day moving average (MA) of 9.34, below the 50-day MA of 9.43, and above the 200-day MA of 8.61, indicating a neutral trend. The MACD of -0.18 indicates Positive momentum. The RSI at 40.03 is Neutral, neither overbought nor oversold. The STOCH value of 9.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ANGO.
AngioDynamics Risk Analysis
AngioDynamics disclosed 34 risk factors in its most recent earnings report. AngioDynamics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AngioDynamics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | $1.85B | 40.70 | 13.77% | 0.83% | 13.19% | 31.73% | |
69 Neutral | $5.49B | 45.55 | 9.16% | ― | 8.24% | 18.54% | |
58 Neutral | $923.17M | 55.81 | -5.16% | ― | -2.64% | -193.31% | |
58 Neutral | $5.33B | 38.74 | 3.48% | 1.13% | 0.29% | -48.98% | |
55 Neutral | $3.31B | ― | -5.76% | ― | 5.28% | -292.14% | |
52 Neutral | $5.23B | 3.70 | -41.86% | 2.84% | 16.58% | -0.16% | |
50 Neutral | $350.44M | ― | -20.46% | ― | -12.56% | 78.70% |
* Healthcare Sector Average
Performance Comparison
ANGO
AngioDynamics
8.77
2.65
43.30%
ICUI
ICU Medical
134.50
28.12
26.43%
LMAT
Lemaitre Vascular
81.60
6.21
8.24%
MMSI
Merit Medical Systems
94.22
14.11
17.61%
STAA
Staar Surgical
19.44
-23.42
-54.64%
TFX
Teleflex
122.08
-81.11
-39.92%
AngioDynamics Earnings Call Summary
Earnings Call Date:Apr 02, 2025
(Q3-2025)
| % Change Since: -9.21%|
Next Earnings Date:Jul 09, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong revenue growth and profitability improvements, particularly in the MedTech and Mechanical Thrombectomy segments. The company increased its guidance for fiscal 2025, indicating confidence in future performance. However, there are ongoing challenges with NanoKnife reimbursement and minimal growth in the Med Device segment. Overall, the positive aspects significantly outweigh the lowlights.Q3-2025 Updates
Positive Updates
Strong Revenue Growth
Total worldwide revenue was $72 million, representing growth of over 9% year-over-year. MedTech segment grew 22%, and Auryon platform revenue increased by 17%.
Mechanical Thrombectomy Segment Success
Mechanical Thrombectomy products, AlphaVac and AngioVac, in combination grew approximately 47% over the second quarter of last year. AlphaVac revenue increased by over 160%.
Improving Profitability
Reported positive adjusted EBITDA of $1.3 million compared to a loss of $3.6 million in the prior year. Adjusted EPS loss improved from $0.16 to $0.08 per share.
Guidance Increase
Guidance increased for total revenue, MedTech growth, gross margin, adjusted EBITDA, and adjusted EPS for the fiscal year 2025.
Negative Updates
NanoKnife Reimbursement Challenges
Despite NanoKnife's growth, a significant material inflection in adoption and utilization is not expected until the CPT 1 code goes into effect on January 1 of next year.
Minimal Growth in Med Device Segment
Med Device segment revenue was $40.7 million, showing a modest increase of approximately 1% over the previous year.
Company Guidance
During the AngioDynamics Fiscal Year 2025 Third Quarter Earnings Call, the company increased its guidance for the year following strong performance. Total worldwide revenue was reported at $72 million, marking a 9% year-over-year increase. The MedTech segment grew by 22%, driven by platforms like Auryon, which saw a 17% increase, and the Mechanical Thrombectomy business, which grew by approximately 47%. The company's gross margin improved to 54%, up by 290 basis points compared to the previous year. Adjusted EBITDA turned positive at $1.3 million, contrasting with a $3.6 million loss in the same quarter of the previous fiscal year, and adjusted EPS was a loss of $0.08 per share, an improvement from the $0.16 loss per share recorded last year. AngioDynamics' updated guidance projects fiscal 2025 total revenue between $285 million and $288 million, with MedTech growth expected to be 14% to 16% and a gross margin range of 53% to 54%.AngioDynamics Corporate Events
Product-Related AnnouncementsBusiness Operations and Strategy
AngioDynamics to Host Virtual Cardiovascular Investor Event
Positive
Apr 2, 2025
On April 2, 2025, AngioDynamics will host a virtual Cardiovascular Investor Event, highlighting its innovative technologies and improved patient outcomes in cardiovascular care. The event underscores AngioDynamics’ strategic focus on growth within the high-growth cardiovascular disease market, leveraging its comprehensive portfolio and differentiated technologies to strengthen its competitive position.
Product-Related AnnouncementsPrivate Placements and FinancingBusiness Operations and StrategyFinancial Disclosures
AngioDynamics Reports Strong Q3 2025 Financial Results
Positive
Apr 2, 2025
AngioDynamics reported its fiscal third quarter 2025 results, highlighting a 9.2% increase in net sales to $72.0 million, driven by a 22.2% growth in MedTech sales. The company achieved a GAAP gross margin of 54.0% and improved its adjusted EBITDA to $1.3 million, reflecting strategic focus on MedTech markets. Key developments include FDA clearance for the NanoKnife System for prostate tissue ablation and the initiation of the AMBITION BTK trial for the Auryon Atherectomy System. AngioDynamics also secured a $25 million revolving line of credit from J.P. Morgan, enhancing financial flexibility.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.